Revision on SomnoMed

SomnoMed recently downgraded their FY15 sales guidance on the back of a poor 3Q sales result, but flag 4Q as a record setting quarter due to the growth of direct sales in the US and strong emerging markets in Europe. SOM has completed testing on the digital record transmission and will be phasing this in across their 14 services hubs over the next 7 months, saving on freight costs, higher levels of precision, and a shortened turnaround time. Following the sales guidance downgrade, we maintain an Add recommendation but revise our price target to A$2.82 (from A$3.26). Research attached access the blog site here: (VIEW LINK)


1 stock mentioned

Scott Power
Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

trending on livewire
Get the best of Livewire by signing up to our popular daily newsletter